Eleven Biotherapeutics Stock Price, News & Analysis (NASDAQ:EBIO)

$0.69 0.01 (1.47 %)
(As of 12/11/2017 02:43 AM ET)
Previous Close$0.68
Today's Range$0.68 - $0.71
52-Week Range$0.62 - $2.54
Volume1.80 million shs
Average Volume519,954 shs
Market Capitalization$21.96 million
P/E RatioN/A
Dividend YieldN/A
Beta3.04

About Eleven Biotherapeutics (NASDAQ:EBIO)

Eleven Biotherapeutics logoEleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company's product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis. The Company's therapeutic approach is based on the role of cytokines in diseases of the eye, its understanding of the structural biology of cytokines and its ability to design and engineer proteins to modulate the effects of cytokines. The Company is developing EBI-031 as an intravitreal injection for DME and uveitis. In addition to EBI-031, the Company has another product candidate in early preclinical development, which is designed to block vascular endothelial growth factor (VEGF).

Receive EBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for EBIO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EBIO
CUSIPN/A
Phone617-871-9911

Debt

Debt-to-Equity RatioN/A
Current Ratio2.75%
Quick Ratio2.75%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$29.98 million
Price / Sales0.73
Cash Flow$0.04 per share
Price / Cash17.40
Book Value$1.60 per share
Price / Book0.43

Profitability

Trailing EPS($1.07)
Net Income$1.89 million
Net Margins11.28%
Return on Equity-94.68%
Return on Assets-29.28%

Miscellaneous

Employees35
Outstanding Shares31,830,000

Eleven Biotherapeutics (NASDAQ:EBIO) Frequently Asked Questions

What is Eleven Biotherapeutics' stock symbol?

Eleven Biotherapeutics trades on the NASDAQ under the ticker symbol "EBIO."

How were Eleven Biotherapeutics' earnings last quarter?

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) released its earnings results on Friday, August, 12th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter. The biopharmaceutical company earned $0.28 million during the quarter. Eleven Biotherapeutics had a net margin of 11.28% and a negative return on equity of 94.68%. View Eleven Biotherapeutics' Earnings History.

Who are some of Eleven Biotherapeutics' key competitors?

Who are Eleven Biotherapeutics' key executives?

Eleven Biotherapeutics' management team includes the folowing people:

  • Daniel S. Lynch, Chairman of the Board (Age 59)
  • Stephen A. Hurly, President, Chief Executive Officer, Director (Age 48)
  • Richard F. Fitzgerald CPA, Interim Chief Financial Officer (Age 54)
  • Glen C. MacDonald Ph.D., Chief Scientific Officer (Age 57)
  • Gregory P. Adams Ph.D., Chief Development Officer (Age 56)
  • Abbie C. Celniker Ph.D., Director (Age 57)
  • Paul G. Chaney, Director (Age 59)
  • Wendy L. Dixon Ph.D., Director (Age 61)
  • Jay S. Duker MD., Director (Age 56)
  • Barry J. Gertz M.D. Ph.D., Director (Age 65)

Who owns Eleven Biotherapeutics stock?

Eleven Biotherapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Municipal Employees Retirement System of Michigan (0.98%). Company insiders that own Eleven Biotherapeutics stock include Abbie Celniker, Boxer Capital, Llc, Eric Steven Furfine, John J Mccabe, Karen L Tubridy, Ventures Fund 2007 L Flagship and Ventures Fund Iv LP Flagship. View Institutional Ownership Trends for Eleven Biotherapeutics.

Who bought Eleven Biotherapeutics stock? Who is buying Eleven Biotherapeutics stock?

Eleven Biotherapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Municipal Employees Retirement System of Michigan. View Insider Buying and Selling for Eleven Biotherapeutics.

How do I buy Eleven Biotherapeutics stock?

Shares of Eleven Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eleven Biotherapeutics' stock price today?

One share of Eleven Biotherapeutics stock can currently be purchased for approximately $0.69.

How big of a company is Eleven Biotherapeutics?

Eleven Biotherapeutics has a market capitalization of $21.96 million and generates $29.98 million in revenue each year. The biopharmaceutical company earns $1.89 million in net income (profit) each year or ($1.07) on an earnings per share basis. Eleven Biotherapeutics employs 35 workers across the globe.

How can I contact Eleven Biotherapeutics?

Eleven Biotherapeutics' mailing address is 215 FIRST STREET SUITE 400, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-9911 or via email at [email protected]com.


MarketBeat Community Rating for Eleven Biotherapeutics (EBIO)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  51 (Vote Outperform)
Underperform Votes:  61 (Vote Underperform)
Total Votes:  112
MarketBeat's community ratings are surveys of what our community members think about Eleven Biotherapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Eleven Biotherapeutics (NASDAQ:EBIO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AHold
Consensus Rating Score: N/AN/AN/A2.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Eleven Biotherapeutics (NASDAQ:EBIO) Consensus Price Target History

Price Target History for Eleven Biotherapeutics (NASDAQ:EBIO)

Eleven Biotherapeutics (NASDAQ:EBIO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/19/2016CitigroupDowngradeBuy -> NeutralN/AView Rating Details
1/18/2016Leerink SwannDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 12/11/2015 forward)

Earnings

Eleven Biotherapeutics (NASDAQ:EBIO) Earnings History and Estimates Chart

Earnings by Quarter for Eleven Biotherapeutics (NASDAQ:EBIO)

Eleven Biotherapeutics (NASDAQ EBIO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2017Q2 2017($0.30)ViewN/AView Earnings Details
5/4/2017Q1 2017($0.25)$0.43 millionViewListenView Earnings Details
3/24/2017Q4 2016($0.12)($0.20)$0.83 millionViewN/AView Earnings Details
11/14/2016Q3($0.17)$0.91$28.70 millionViewListenView Earnings Details
8/12/2016Q2($0.33)$0.28 millionViewN/AView Earnings Details
3/24/2016Q4($0.32)($0.53)$0.57 millionViewN/AView Earnings Details
11/4/2015Q315($0.44)($0.50)$0.10 million$0.07 millionViewListenView Earnings Details
8/13/2015Q215($0.43)($0.36)$0.20 million$0.11 millionViewListenView Earnings Details
4/30/2015Q115($0.57)($0.36)$0.20 million$0.24 millionViewListenView Earnings Details
3/4/2015Q414($0.33)($0.49)$0.80 million$0.38 millionViewListenView Earnings Details
11/13/2014Q314($0.45)($0.66)$0.70 million$0.54 millionViewN/AView Earnings Details
8/13/2014Q2 2014($0.47)($0.51)$0.10 million$0.76 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Eleven Biotherapeutics (NASDAQ:EBIO) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Eleven Biotherapeutics (NASDAQ:EBIO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Eleven Biotherapeutics (NASDAQ EBIO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 28.70%
Institutional Ownership Percentage: 4.19%
Insider Trades by Quarter for Eleven Biotherapeutics (NASDAQ:EBIO)
Institutional Ownership by Quarter for Eleven Biotherapeutics (NASDAQ:EBIO)

Eleven Biotherapeutics (NASDAQ EBIO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/28/2016Abbie CelnikerDirectorSell10,031$3.00$30,093.00View SEC Filing  
9/23/2016Ventures Fund 2007 L FlagshipMajor ShareholderSell443,422$3.16$1,401,213.52View SEC Filing  
9/21/2016Ventures Fund Iv L.P FlagshipMajor ShareholderSell322,723$3.75$1,210,211.25View SEC Filing  
9/20/2016Ventures Fund Iv L.P FlagshipMajor ShareholderSell53,917$3.39$182,778.63View SEC Filing  
9/19/2016Ventures Fund Iv L.P FlagshipMajor ShareholderSell9,700$3.31$32,107.00View SEC Filing  
9/15/2016Ventures Fund 2007 L FlagshipMajor ShareholderSell46,692$4.18$195,172.56View SEC Filing  
9/7/2016Ventures Fund 2007 L FlagshipMajor ShareholderSell129,497$4.54$587,916.38View SEC Filing  
8/15/2016John J MccabeCFOSell1,170$4.80$5,616.00View SEC Filing  
6/27/2016Abbie CelnikerCEOSell10,029$2.08$20,860.32View SEC Filing  
6/27/2016Karen L TubridyInsiderSell4,372$2.08$9,093.76View SEC Filing  
6/13/2016Boxer Capital, LlcMajor ShareholderSell1,042,000$2.74$2,855,080.00View SEC Filing  
2/16/2016John J MccabeSVPSell1,501$0.27$405.27View SEC Filing  
12/28/2015Abbie CelnikerCEOSell10,155$2.85$28,941.75View SEC Filing  
12/28/2015Eric Steven FurfineInsiderSell4,652$2.85$13,258.20View SEC Filing  
5/8/2015Jafco Super V3 Investment LimiMajor ShareholderSell33,400$13.23$441,882.00View SEC Filing  
2/2/2015Jafco Super V3 Investment LimiMajor ShareholderSell17,900$11.62$207,998.00View SEC Filing  
1/30/2015Jafco Super V3 Investment LimiMajor ShareholderSell120,000$11.62$1,394,400.00View SEC Filing  
1/26/2015Jafco Super V3 Investment LimiMajor ShareholderSell6,300$11.85$74,655.00View SEC Filing  
1/22/2015Jafco Super V3 Investment LimiMajor ShareholderSell6,300$11.82$74,466.00View SEC Filing  
1/16/2015Jafco Super V3 Investment LimiMajor ShareholderSell6,100$12.07$73,627.00View SEC Filing  
8/26/2014Jafco Super V3 Investment LimiMajor ShareholderSell2,000$11.54$23,080.00View SEC Filing  
8/20/2014Jafco Super V3 Investment LimiMajor ShareholderSell1,165$11.54$13,444.10View SEC Filing  
8/18/2014Jafco Super V3 Investment LimiMajor ShareholderSell2,600$11.81$30,706.00View SEC Filing  
8/14/2014Jafco Super V3 Investment LimiMajor ShareholderSell2,000$11.75$23,500.00View SEC Filing  
2/11/2014Jafco Super V3 Investment LimiMajor ShareholderBuy219,790$10.00$2,197,900.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Eleven Biotherapeutics (NASDAQ EBIO) News Headlines

Source:
DateHeadline
Eleven Biotherapeutics to Present at the LD Micro Main Event 2017Eleven Biotherapeutics to Present at the LD Micro Main Event 2017
finance.yahoo.com - November 30 at 5:10 PM
Eleven Biotherapeutics Reports Third Quarter 2017 Financial Results - Business Wire (press release)Eleven Biotherapeutics Reports Third Quarter 2017 Financial Results - Business Wire (press release)
www.businesswire.com - November 21 at 12:03 AM
Eleven Biotherapeutics Reports Third Quarter 2017 Financial ResultsEleven Biotherapeutics Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 20 at 6:58 PM
Eleven Biotherapeutics, Inc.: Sudden move in price, will it continue?Eleven Biotherapeutics, Inc.: Sudden move in price, will it continue?
finance.yahoo.com - November 20 at 6:58 PM
Eleven Biotherapeutics (EBIO) Presents At Stifel 2017 Healthcare Conference - SlideshowEleven Biotherapeutics (EBIO) Presents At Stifel 2017 Healthcare Conference - Slideshow
seekingalpha.com - November 16 at 6:42 PM
Edited Transcript of EBIO earnings conference call or presentation 14-Nov-17 9:30pm GMTEdited Transcript of EBIO earnings conference call or presentation 14-Nov-17 9:30pm GMT
finance.yahoo.com - November 16 at 1:41 PM
Eleven Biotherapeutics (EBIO) CEO Stephen Hurly on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaEleven Biotherapeutics' (EBIO) CEO Stephen Hurly on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 14 at 11:32 PM
Eleven Biotherapeutics, Inc. to Host Earnings CallEleven Biotherapeutics, Inc. to Host Earnings Call
finance.yahoo.com - November 14 at 6:32 PM
Eleven Biotherapeutics (EBIO) versus Ra Pharmctl (RARX) Head-To-Head AnalysisEleven Biotherapeutics (EBIO) versus Ra Pharmctl (RARX) Head-To-Head Analysis
www.americanbankingnews.com - November 10 at 11:28 PM
Eleven Biotherapeutics to Present at Stifel 2017 Healthcare ConferenceEleven Biotherapeutics to Present at Stifel 2017 Healthcare Conference
finance.yahoo.com - November 10 at 11:47 AM
Eleven Biotherapeutics to Report Third Quarter 2017 Financial Results on November 14, 2017Eleven Biotherapeutics to Report Third Quarter 2017 Financial Results on November 14, 2017
finance.yahoo.com - November 10 at 11:47 AM
Eleven Biotherapeutics Announces Closing of $8.0 Million Underwritten Public Offering - Business Wire (press release)Eleven Biotherapeutics Announces Closing of $8.0 Million Underwritten Public Offering - Business Wire (press release)
www.businesswire.com - November 3 at 6:24 PM
Eleven Biotherapeutics Announces Closing of $8.0 Million Underwritten Public OfferingEleven Biotherapeutics Announces Closing of $8.0 Million Underwritten Public Offering
finance.yahoo.com - November 3 at 6:24 PM
Eleven Bio prices equity offering; shares down 24% - Seeking AlphaEleven Bio prices equity offering; shares down 24% - Seeking Alpha
seekingalpha.com - November 3 at 1:23 PM
Eleven Biotherapeutics (EBIO) Prices $8M Offing of Common Stock and WarrantsEleven Biotherapeutics (EBIO) Prices $8M Offing of Common Stock and Warrants
www.streetinsider.com - November 1 at 7:05 PM
Eleven Biotherapeutics Prices of $8.0 Million Underwritten Public OfferingEleven Biotherapeutics Prices of $8.0 Million Underwritten Public Offering
finance.yahoo.com - November 1 at 7:05 PM
Financial Contrast: Eleven Biotherapeutics (EBIO) vs. Its RivalsFinancial Contrast: Eleven Biotherapeutics (EBIO) vs. Its Rivals
www.americanbankingnews.com - October 23 at 8:30 PM
Eleven Biotherapeutics (EBIO) Names Richard Fitzgerald as Interim CFO - StreetInsider.comEleven Biotherapeutics (EBIO) Names Richard Fitzgerald as Interim CFO - StreetInsider.com
www.streetinsider.com - October 14 at 10:54 PM
Eleven Biotherapeutics (EBIO) Names Richard Fitzgerald as Interim CFOEleven Biotherapeutics (EBIO) Names Richard Fitzgerald as Interim CFO
www.streetinsider.com - October 13 at 11:39 PM
Eleven Biotherapeutics Appoints Richard Fitzgerald as Interim Chief Financial OfficerEleven Biotherapeutics Appoints Richard Fitzgerald as Interim Chief Financial Officer
finance.yahoo.com - October 13 at 6:38 PM
Financial Analysis: Eleven Biotherapeutics (EBIO) vs. Clovis Oncology (CLVS)Financial Analysis: Eleven Biotherapeutics (EBIO) vs. Clovis Oncology (CLVS)
www.americanbankingnews.com - October 12 at 8:12 AM
Eleven Biotherapeutics (EBIO) versus Its Rivals Head-To-Head ContrastEleven Biotherapeutics (EBIO) versus Its Rivals Head-To-Head Contrast
www.americanbankingnews.com - September 30 at 12:30 AM
Eleven Biotherapeutics (EBIO) Completes Vicinium Manufacturing for Ongoing Clinical Trials in NMIBC - StreetInsider.comEleven Biotherapeutics (EBIO) Completes Vicinium Manufacturing for Ongoing Clinical Trials in NMIBC - StreetInsider.com
www.streetinsider.com - September 22 at 8:46 AM
Eleven Biotherapeutics Announces Completion of Vicinium Manufacturing for Ongoing Clinical Trials in Non-Muscle Invasive Bladder CancerEleven Biotherapeutics Announces Completion of Vicinium Manufacturing for Ongoing Clinical Trials in Non-Muscle Invasive Bladder Cancer
finance.yahoo.com - September 22 at 8:46 AM
Eleven Bio breaks out, shares ahead 38% - Seeking AlphaEleven Bio breaks out, shares ahead 38% - Seeking Alpha
seekingalpha.com - September 9 at 5:02 AM
Eleven Biotherapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment ConferenceEleven Biotherapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
finance.yahoo.com - September 5 at 7:44 PM
Eleven Biotherapeutics, Inc. (EBIO) Posts  Earnings ResultsEleven Biotherapeutics, Inc. (EBIO) Posts Earnings Results
www.americanbankingnews.com - August 15 at 1:10 PM
Edited Transcript of EBIO earnings conference call or presentation 14-Aug-17 12:00pm GMTEdited Transcript of EBIO earnings conference call or presentation 14-Aug-17 12:00pm GMT
finance.yahoo.com - August 14 at 11:29 PM
Eleven Biotherapeutics Reports Second Quarter 2017 Financial Results - Business Wire (press release)Eleven Biotherapeutics Reports Second Quarter 2017 Financial Results - Business Wire (press release)
www.businesswire.com - August 14 at 6:27 PM
Eleven Biotherapeutics Reports Second Quarter 2017 Financial ResultsEleven Biotherapeutics Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 14 at 6:27 PM
Eleven Biotherapeutics to Report Second Quarter 2017 Financial Results on Monday, August 14, 2017Eleven Biotherapeutics to Report Second Quarter 2017 Financial Results on Monday, August 14, 2017
finance.yahoo.com - August 7 at 6:25 PM
Eleven Biotherapeutics to Present at Canaccord Genuity 37 - Business Wire (press release)Eleven Biotherapeutics to Present at Canaccord Genuity 37 - Business Wire (press release)
www.businesswire.com - August 3 at 5:07 PM
Eleven Biotherapeutics to Present at Canaccord Genuity 37th Annual Growth ConferenceEleven Biotherapeutics to Present at Canaccord Genuity 37th Annual Growth Conference
finance.yahoo.com - August 3 at 5:07 PM
Todays Research Report Coverage on Biotech Stocks -- Eleven Biotherapeutics, Egalet, Aevi Genomic Medicine, and ... - PR Newswire (press release)Today's Research Report Coverage on Biotech Stocks -- Eleven Biotherapeutics, Egalet, Aevi Genomic Medicine, and ... - PR Newswire (press release)
www.prnewswire.com - July 18 at 7:38 PM
ETFs with exposure to Eleven Biotherapeutics, Inc. : July 13, 2017ETFs with exposure to Eleven Biotherapeutics, Inc. : July 13, 2017
finance.yahoo.com - July 13 at 7:26 PM
Eleven Biotherapeutics (EBIO) Presents At 2017 Marcum Microcap Conference - SlideshowEleven Biotherapeutics (EBIO) Presents At 2017 Marcum Microcap Conference - Slideshow
seekingalpha.com - June 20 at 12:38 AM
Eleven Biotherapeutics (EBIO) to Partner with AstraZeneca (AZN) & National Cancer Institute on Development of ... - StreetInsider.comEleven Biotherapeutics (EBIO) to Partner with AstraZeneca (AZN) & National Cancer Institute on Development of ... - StreetInsider.com
www.streetinsider.com - June 6 at 10:16 PM
Eleven Biotherapeutics Announces Data and Safety Monitoring Board (DSMB) Recommendation to Continue Phase 3 Registration Trial with Vicinium™ in Non-Muscle Invasive Bladder ...Eleven Biotherapeutics Announces Data and Safety Monitoring Board (DSMB) Recommendation to Continue Phase 3 Registration Trial with Vicinium™ in Non-Muscle Invasive Bladder ...
www.businesswire.com - June 2 at 4:19 PM
Eleven Biotherapeutics (EBIO) Report Data & Safety Monitoring Board Recommendation to Continue Phase 3 ... - StreetInsider.comEleven Biotherapeutics (EBIO) Report Data & Safety Monitoring Board Recommendation to Continue Phase 3 ... - StreetInsider.com
www.streetinsider.com - June 1 at 5:36 PM
Eleven Biotherapeutics (EBIO) Report Data & Safety Monitoring Board Recommendation to Continue Phase 3 ... - StreetInsider.comEleven Biotherapeutics (EBIO) Report Data & Safety Monitoring Board Recommendation to Continue Phase 3 ... - StreetInsider.com
www.streetinsider.com - June 1 at 5:36 PM
Eleven Biotherapeutics Continues Expansion of Clinical ... - Business Wire (press release)Eleven Biotherapeutics Continues Expansion of Clinical ... - Business Wire (press release)
www.businesswire.com - May 17 at 4:54 PM
Eleven Biotherapeutics (EBIO) Presents New Preclinical Data With ... - StreetInsider.comEleven Biotherapeutics (EBIO) Presents New Preclinical Data With ... - StreetInsider.com
www.streetinsider.com - April 4 at 7:07 AM
ELEVEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsELEVEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - April 4 at 7:07 AM
Eleven Biotherapeutics (EBIO) to Present New Preclinical Data at AACREleven Biotherapeutics (EBIO) to Present New Preclinical Data at AACR
www.streetinsider.com - March 28 at 12:04 PM
Eleven Biotherapeutics (EBIO) Gains Ahead of Q4 EarningsEleven Biotherapeutics (EBIO) Gains Ahead of Q4 Earnings
www.baystreet.ca - March 26 at 4:36 PM
Q4 2016 Eleven Biotherapeutics Inc Earnings Release - Time Not SuppliedQ4 2016 Eleven Biotherapeutics Inc Earnings Release - Time Not Supplied
biz.yahoo.com - March 24 at 9:40 AM
ELEVEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial ConditionELEVEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
biz.yahoo.com - March 24 at 9:40 AM
Eleven Biotherapeutics (EBIO) Presents At Oppenheimer 27th Annual Healthcare ConferenceEleven Biotherapeutics (EBIO) Presents At Oppenheimer 27th Annual Healthcare Conference
seekingalpha.com - March 22 at 4:59 PM
ELEVEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal OfficersELEVEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - March 7 at 11:55 AM
Eleven Biotherapeutics (EBIO) Presents At 19th Annual BIO CEO & Investor Conference - SlideshowEleven Biotherapeutics (EBIO) Presents At 19th Annual BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 16 at 8:41 PM

SEC Filings

Eleven Biotherapeutics (NASDAQ:EBIO) SEC Filings

DateFilerForm TypeView

Social Media

Financials

Eleven Biotherapeutics (NASDAQ:EBIO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Eleven Biotherapeutics (NASDAQ EBIO) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.